From China to the United States, PERSEUS scientists presented pioneering results on 2D nanomaterials for cancer therapy at the world’s most prestigious scientific gatherings.
During its second reporting period, the PERSEUS consortium brought its groundbreaking research to an impressive series of international conferences, underscoring its growing leadership in the field of nanomedicine. PERSEUS researchers took part in several major scientific events — including MRS Fall 2024 in Boston, Graphene 2025 in Dresden, ChinaNano 2025 in Beijing, and the European Symposium on Organic Chemistry (ESOC 2025) — sharing new results on multifunctional two-dimensional (2D) materials for precision cancer therapy.
A central highlight was the symposium “2D Materials for Theranostics” organised within the Materials Research Society (MRS) Fall 2024 Meeting, one of the most respected venues in materials science. The PERSEUS-led symposium drew over 12 invited speakers, 20 contributed talks, and 34 poster presentations, including six from project partners. The sessions covered the full spectrum of PERSEUS innovation — from material synthesis and functionalisation, to imaging, biocompatibility, and low-energy X-ray activation for cancer treatment. The event demonstrated how European collaboration in advanced materials can shape the next generation of personalised medicine.
Beyond MRS, PERSEUS results were also presented at Graphene 2025, the world’s largest conference dedicated to graphene and 2D materials, and at ChinaNano 2025, a major showcase of nanoscience research in Asia. These appearances strengthened the project’s visibility across continents, creating valuable bridges with international research communities and industrial partners.
Scientific leadership was further amplified through invited lectures by consortium members, such as Prof. Bengt Fadeel (Karolinska Institutet) and Prof. Avi Schroeder (Technion – Israel Institute of Technology), whose talks explored the promise of smart nanocarriers and biocompatible functionalisation for targeted therapy. Such contributions helped position PERSEUS as a global reference point for translational nanotechnology and safe, responsible innovation in health.
By participating in high-profile events worldwide, PERSEUS continues to advance its mission of leveraging nanomaterials to fight cancer — combining European scientific excellence with global outreach. The project’s consistent presence on the international stage not only highlights its technical achievements but also reinforces its commitment to open collaboration, ethical research, and societal impact.
